Trial Profile
A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Lamivudine/abacavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Apr 2019 The study has been completed in Belgium.
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 19 Oct 2018 Planned End Date changed from 1 Nov 2018 to 1 Mar 2019.